Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

Benralizumab is an anti-eosinophilic monoclonal antibody that reduces exacerbations and improves lung function for patients with severe, uncontrolled asthma with eosinophilic inflammation. We evaluated the impact of baseline factors on benralizumab efficacy for patients with severe asthma. This anal...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Respir J
Main Authors: Bleecker, Eugene R., Wechsler, Michael E., FitzGerald, J. Mark, Menzies-Gow, Andrew, Wu, Yanping, Hirsch, Ian, Goldman, Mitchell, Newbold, Paul, Zangrilli, James G.
Formato: Artigo
Idioma:Inglês
Publicado em: European Respiratory Society 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6203407/
https://ncbi.nlm.nih.gov/pubmed/30139780
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.00936-2018
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados